8JD Stock Overview
Engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Valbiotis SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.24 |
| 52 Week High | €5.68 |
| 52 Week Low | €1.08 |
| Beta | -0.16 |
| 11 Month Change | -2.98% |
| 3 Month Change | -31.49% |
| 1 Year Change | -78.16% |
| 33 Year Change | -81.10% |
| 5 Year Change | n/a |
| Change since IPO | -84.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8JD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.4% | 0.8% | -1.3% |
| 1Y | -78.2% | -17.5% | 7.4% |
Return vs Industry: 8JD underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 8JD underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 8JD volatility | |
|---|---|
| 8JD Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8JD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8JD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 52 | Sebastien Peltier | www.valbiotis.com |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD.
Valbiotis SA Fundamentals Summary
| 8JD fundamental statistics | |
|---|---|
| Market cap | €19.51m |
| Earnings (TTM) | -€8.94m |
| Revenue (TTM) | €527.00k |
37.0x
P/S Ratio-2.2x
P/E RatioIs 8JD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8JD income statement (TTM) | |
|---|---|
| Revenue | €527.00k |
| Cost of Revenue | €3.00m |
| Gross Profit | -€2.48m |
| Other Expenses | €6.47m |
| Earnings | -€8.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | -470.02% |
| Net Profit Margin | -1,697.15% |
| Debt/Equity Ratio | 29.6% |
How did 8JD perform over the long term?
See historical performance and comparison